Core Viewpoint - Citigroup has raised the target price for Fosun Pharma from HKD 25 to HKD 35.3, maintaining a "Buy" rating, reflecting positive adjustments in revenue and earnings forecasts for the years 2025 to 2027 [1] Revenue and Earnings Forecasts - Revenue forecasts for 2025, 2026, and 2027 have been increased by 0.5%, 2%, and 3% respectively [1] - Earnings per share forecasts have been adjusted upward by 3%, 8%, and 6% for the same years [1] Factors Influencing Adjustments - The adjustments are attributed to aggressive employee stock ownership goals, ongoing project monetization potential from external licensing deals, and improved operational efficiency from restructuring the R&D framework [1]